NYSEAMERICAN:TOVX Theriva Biologics (TOVX) Stock Price, News & Analysis $1.28 +0.02 (+1.59%) (As of 03:00 PM ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartEarningsHeadlinesInsider TradesOwnershipShort Interest About Theriva Biologics Stock (NYSEAMERICAN:TOVX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Theriva Biologics alerts:Sign Up Key Stats Today's Range$1.23▼$1.3250-Day Range N/A52-Week Range$1.22▼$17.11Volume50,232 shsAverage Volume982,419 shsMarket Capitalization$3.56 millionP/E RatioN/ADividend YieldN/APrice Target$6.00Consensus RatingBuy Company OverviewTheriva Biologics, Inc., a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States. The company's lead product candidate is VCN-01, a clinical stage oncolytic human adenovirus that is in a Phase 2 clinical study for the treatment of pancreatic cancer; a Phase 1 clinical study for the treatment of retinalblastoma; a Phase 1 clinical study for the treatment of head and neck squamous cell carcinoma; and a Phase 1 clinical study for the treatment of solid tumors. It also develops VCN-11 for treating solid tumors; SYN-004 designed to degrade various commonly used intravenous beta-lactam antibiotics in gastrointestinal (GI) tract for the prevention of microbiome damage to prevent overgrowth and infection by pathogenic organisms, such Clostridioides difficile infection and vancomycin resistant Enterococci, and reducing the incidence and severity of acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant recipients; and SYN-020, a recombinant oral formulation for the enzyme intestinal alkaline phosphatase to treat both local GI and systemic diseases. In addition, the company develops clinical stage products, such as SYN-006 to prevent aGVHD and infection by carbapenem resistant enterococci; and SYN-007 for preventing antibiotic associated diarrhea with oral ß-lactam antibiotics. It has collaboration agreements with The University of Texas at Austin, Catalan Institute of Oncology, Fundació Privada Institut d'Investigacio Biomedica de Bellvitge, Saint Joan De Déu, and Massachusetts General Hospital, as well as a clinical trial agreement with Washington University School of Medicine in St. Louis to conduct a Phase 1b/2a clinical trial of SYN-004. Theriva Biologics, Inc. is headquartered in Rockville, Maryland.Read More… Download Our Tesla Ebook For Free (Ad)Like many of you, we here at the TradingPub are bullish on Tesla long term. We believe the company will continue to be a leader in technology, EVs and A.I. We also believe it’s share price will be rewarded in a big way… In fact, our #1 Tesla expert just published a brand new Ebook regarding Tesla’s future, and we’d like to send it to you at no cost.To claim your copy free of charge simply follow this link. Theriva Biologics Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks34th Percentile Overall ScoreTOVX MarketRank™: Theriva Biologics scored higher than 34% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingTheriva Biologics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageTheriva Biologics has only been the subject of 1 research reports in the past 90 days.Read more about Theriva Biologics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Theriva Biologics is -0.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Theriva Biologics is -0.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioTheriva Biologics has a P/B Ratio of 0.14. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted4.10% of the float of Theriva Biologics has been sold short.Short Interest Ratio / Days to CoverTheriva Biologics has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Theriva Biologics has recently increased by 15.19%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldTheriva Biologics does not currently pay a dividend.Dividend GrowthTheriva Biologics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted4.10% of the float of Theriva Biologics has been sold short.Short Interest Ratio / Days to CoverTheriva Biologics has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Theriva Biologics has recently increased by 15.19%, indicating that investor sentiment is decreasing significantly. News and Social Media0.6 / 5News SentimentN/A News SentimentTheriva Biologics has a news sentiment score of -0.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.47 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Theriva Biologics this week, compared to 1 article on an average week.Search InterestOnly 4 people have searched for TOVX on MarketBeat in the last 30 days. This is a decrease of -69% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Theriva Biologics to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Theriva Biologics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 3.05% of the stock of Theriva Biologics is held by insiders.Percentage Held by InstitutionsOnly 6.17% of the stock of Theriva Biologics is held by institutions.Read more about Theriva Biologics' insider trading history. Receive TOVX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Theriva Biologics and its competitors with MarketBeat's FREE daily newsletter. Email Address TOVX Stock News HeadlinesTheriva Biologics (NYSEAMERICAN:TOVX) Price Target Lowered to $6.00 at Maxim GroupNovember 15, 2024 | americanbankingnews.comTheriva Biologics Highlights Key Achievements in Q3 2024November 14, 2024 | tipranks.comDownload Our Tesla Ebook For FreeLike many of you, we here at the TradingPub are bullish on Tesla long term. We believe the company will continue to be a leader in technology, EVs and A.I. We also believe it’s share price will be rewarded in a big way… In fact, our #1 Tesla expert just published a brand new Ebook regarding Tesla’s future, and we’d like to send it to you at no cost.November 21, 2024 | DTI (Ad)Theriva™ Biologics Reports Third Quarter 2024 Operational Highlights and Financial ResultsNovember 13, 2024 | markets.businessinsider.comTheriva Biologics, Inc.: Theriva Biologics Reports Third Quarter 2024 Operational Highlights and Financial ResultsNovember 12, 2024 | finanznachrichten.de3 Penny Stocks to Watch Now, 11/5/24November 5, 2024 | msn.comTheriva Biologics Expands Stock Plans and Share AuthorityNovember 2, 2024 | markets.businessinsider.comWhat's Going On With Theriva Biologics Stock Friday?November 2, 2024 | msn.comSee More Headlines TOVX Stock Analysis - Frequently Asked Questions How were Theriva Biologics' earnings last quarter? Theriva Biologics, Inc. (NYSEAMERICAN:TOVX) released its quarterly earnings results on Tuesday, November, 12th. The company reported ($6.81) earnings per share (EPS) for the quarter, missing the consensus estimate of ($6.25) by $0.56. When did Theriva Biologics' stock split? Shares of Theriva Biologics reverse split on the morning of Monday, August 26th 2024. The 1-25 reverse split was announced on Friday, August 16th 2024. The number of shares owned by shareholders was adjusted after the market closes on Friday, August 23rd 2024. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split. Who are Theriva Biologics' major shareholders? Top institutional investors of Theriva Biologics include Anson Funds Management LP (6.13%) and MSD Partners L.P. (1.20%). View institutional ownership trends. How do I buy shares of Theriva Biologics? Shares of TOVX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Theriva Biologics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Theriva Biologics investors own include BIOLASE (BIOL), Jiuzi (JZXN), Daré Bioscience (DARE), Dermata Therapeutics (DRMA), Faraday Future Intelligent Electric (FFIE), Adial Pharmaceuticals (ADIL) and Aditxt (ADTX). Company Calendar Last Earnings11/12/2024Today11/21/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSEAMERICAN SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNYSEAMERICAN:TOVX CUSIPN/A CIKN/A Webtherivabio.com Phone(301) 417-4364Fax301-417-4367Employees22Year FoundedN/APrice Target and Rating Average Stock Price Target$6.00 High Stock Price Target$6.00 Low Stock Price Target$6.00 Potential Upside/Downside+378.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($33.06) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-18,350,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-76.12% Return on Assets-48.54% Debt Debt-to-Equity RatioN/A Current Ratio2.67 Quick Ratio2.67 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$8.85 per share Price / Book0.14Miscellaneous Outstanding Shares2,780,000Free Float2,697,000Market Cap$3.48 million OptionableNot Optionable Beta1.34 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleGrowth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.Get This Free Report This page (NYSEAMERICAN:TOVX) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Theriva Biologics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Theriva Biologics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.